Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 8.09% is 278% above its 5-year average of -4.54%, near the high end of its 5-year range (-19.27%–8.09%).
1364.06% above its 12-month average of -0.64%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-27): 4.97%.
RETURN ON ASSETS (ROA)
8.09%
RETURN ON ASSETS (ROA) AVG TTM
-0.64%
RETURN ON ASSETS (ROA) AVG 3Y
-8.03%
RETURN ON ASSETS (ROA) AVG 5Y
-4.54%
RETURN ON ASSETS (ROA) AVG 10Y
-3.23%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+1364.06%
CURRENT VS 3Y AVG
+200.78%
CURRENT VS 5Y AVG
+278.39%
CURRENT VS 10Y AVG
+350.53%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+127.78%
vs the sector median at left
Bioventus Inc.
Market Cap
$894.27M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$885.96M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$914.14M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$925.11M
Return on Assets (ROA)
-45.94%
TTM Avg
-39.23%
3Y Avg
-37.58%
5Y Avg
-117.41%
Market Cap
$862.71M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$923.25M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$928.46M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$841.42M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$834.78M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bioventus Inc. (BVS) | $894.27M | 8.09% | -0.64% | -8.03% | -4.54% |
| Arbutus Biopharma Corp (ABUS)vs › | $885.96M | 55.85% | -44.25% | -43.62% | -43.05% |
| HealthStream, Inc. (HSTM)vs › | $914.14M | 4.06% | 3.72% | 3.23% | 2.82% |
| MoonLake Immunotherapeutics (MLTX)vs › | $925.11M | -45.94% | -39.23% | -37.58% | -117.41% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $862.71M | -22.62% | -55.95% | -57.94% | -46.38% |
| Kura Oncology, Inc. (KURA)vs › | $923.25M | -50.49% | -30.32% | -31.10% | -27.11% |
| CeriBell, Inc. (CBLL)vs › | $928.46M | -39.67% | -22.62% | -34.56% | -34.56% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $841.42M | -23.15% | -12.59% | -25.36% | -32.38% |
| Beta Bionics, Inc. (BBNX)vs › | $834.78M | -24.96% | -29.43% | -70.30% | -70.30% |
| Alumis Inc. (ALMS)vs › | $825.76M | -78.30% | -72.68% | -105.45% | -105.45% |
ROA
8.1%
ROE
23.9%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.33% |
| 2024-12-31 | -4.61% |
| 2023-12-31 | -19.27% |
| 2022-12-31 | -11.56% |
| 2021-12-31 | 1.58% |
| 2020-12-31 | 3.32% |
| 2019-12-06 | 1.45% |
| 2018-12-31 | -2.76% |
| 2017-12-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2015-12-31 | -7.00% |
| 2014-12-31 | -3.00% |
| 2013-12-31 | 0.00% |
